Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor Prognosis of Diffuse Large B-cell Lymphoma

被引:0
|
作者
Cao, Baoping [1 ]
Guo, Xiaochuan [1 ]
Wang, Bin [1 ]
Wang, Weixia [1 ]
Han, Dong [1 ]
Zhang, Weijing [1 ]
Zhong, Kaili [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Lymphoma, Beijing 100038, Peoples R China
关键词
WEB SERVER; CANCER; AUTOPHAGY; INHIBITION; RESISTANCE; PROLIFERATION; MUCINS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate androgen-regulated mucin-like protein (PARM1) is known to promote cell survival via protecting the cell surface, thus being involved in cancer development. The Gene Expression Profiling Interactive Analysis (GEPIA), MEXPRESS database, LinkedOmics database, GeneMANIA database, and the Tumor Immune Estimation Resource (TIMER) database were accessed to explore the epigenetic regulation, prognostic value, biological functions and mechanisms of PARM1 in diffuse large B-cell lymphoma (DLBCL). Hypomethylation and resultant overexpression of PARM1 was found in DLBCL. The high-level expression of PARM1 was related to the poor outcome of DLBCL patients. PARM1 participated in DNA repair, cell cycle, and cellular response to stress. PARM1 was also associated with autophagy, apoptosis, Ras pathway, and MAPK cascade. Significant kinase targets of PARM1 included ATM, CDK1, and CDK2. Significant transcription factor targets of PARM1 involved ELK1, MYC and so on. Significant miRNA targets of PARM1 included miR21, miR202, miR323, and miR345. Further analysis suggested that the PARM1 regulated autophagy through the PI3K-Akt signaling. PARM1 was found to be correlated with immune cell infiltration, which indicated the important roles of PARM1 in microenvironment of DLBCL. Our study lays a foundation for further research on the impact of PARM1 in DLBCL tumorigenesis and precision therapy.
引用
收藏
页码:27 / 40
页数:14
相关论文
共 50 条
  • [1] Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
    Tsai, Yu-Fen
    Liu, Yi-Chang
    Yang, Ching-, I
    Chuang, Tzer-Ming
    Ke, Ya-Lun
    Yeh, Tsung-Jang
    Gau, Yuh-Ching
    Du, Jeng-Shiun
    Wang, Hui-Ching
    Cho, Shih-Feng
    Hsu, Chin-Mu
    Wu, Pey-Fang
    Huang, Ching-, I
    Huang, Chung-Feng
    Yu, Ming-Lung
    Dai, Chia-Yen
    Hsiao, Hui-Hua
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [2] Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma
    Taskinen, Minna
    Louhimo, Riku
    Koivula, Satu
    Chen, Ping
    Rantanen, Ville
    Holte, Harald
    Delabie, Jan
    Karjalainen-Lindsberg, Marja-Liisa
    Bjorkholm, Magnus
    Fluge, Oystein
    Pedersen, Lars Moller
    Fjorden, Karin
    Jerkeman, Mats
    Eriksson, Mikael
    Hautaniemi, Sampsa
    Leppa, Sirpa
    PLOS ONE, 2014, 9 (03):
  • [3] SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma
    Jang, Kyu Yun
    Hwang, Sung Ho
    Kwon, Keun Sang
    Kim, Kyung Ryoul
    Choi, Ha Na
    Lee, Na-Ri
    Kwak, Jae-Yong
    Park, Byung-Hyun
    Park, Ho Sung
    Chung, Myoung Ja
    Kang, Myoung Jae
    Lee, Dong Geun
    Kim, Hun Soo
    Shim, Hyeok
    Moon, Woo Sung
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (10) : 1523 - 1531
  • [4] LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large B-cell Lymphoma
    Dang, Qingxiu
    Zhou, Hong
    Qian, Juan
    Yang, Li
    Huang, Jianfei
    Zhang, Yaping
    Shi, Wenyu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (11): : 749 - 754
  • [5] Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length
    Carlund, Olivia
    Thorn, Elina
    Osterman, Pia
    Fors, Maja
    Dernstedt, Andy
    Forsell, Mattias N. E.
    Erlanson, Martin
    Landfors, Mattias
    Degerman, Sofie
    Hultdin, Magnus
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [6] CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
    Mingfang Shen
    Yunfeng Zhang
    Lun Tang
    Qinyan Fu
    Jiawei Zhang
    Yang Xu
    Hui Zeng
    Yuan Li
    BMC Cancer, 23
  • [7] CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
    Shen, Mingfang
    Zhang, Yunfeng
    Tang, Lun
    Fu, Qinyan
    Zhang, Jiawei
    Xu, Yang
    Zeng, Hui
    Li, Yuan
    BMC CANCER, 2023, 23 (01)
  • [8] Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
    Boddicker, Nicholas J.
    Desai, Pinkal
    Shah, Mithun Vinod
    Sarangi, Vivekananda
    Maurer, Matthew J.
    Cahn, Elliot J.
    Martin, Peter
    Link, Brian K.
    Witzig, Thomas E.
    Feldman, Andrew L.
    Nowakowski, Grzegorz S.
    Habermann, Thomas M.
    Slager, Susan L.
    Huang, C. Chris
    Towfic, Fadi
    Asmann, Yan
    Gandhi, Anita K.
    Novak, Anne J.
    Cerhan, James R.
    BLOOD, 2020, 136
  • [9] Chromosomal Instability Substantiates Poor Prognosis in Patients with Diffuse Large B-cell Lymphoma
    Bakhoum, Samuel F.
    Danilova, Olga V.
    Kaur, Prabhjot
    Levy, Norman B.
    Compton, Duane A.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7704 - 7711
  • [10] Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis
    Sughayer, M.
    Abbas, M.
    Al-Khateeb, E.
    Khader, M.
    HISTOPATHOLOGY, 2022, 81 : 101 - 102